Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Keiichiro MoriTakahiro KimuraKagenori ItoHajime OnumaMasatoshi TanakaTaishi MatsuuraGaku KurokawaKosuke IwataniYuzo InabaKeigo SakanakaHiroshi SasakiJun MikiTatsuya ShimomuraKenta MikiShin EgawaPublished in: The Prostate (2018)
Early use of ARAT may improve OS, PFS, and PSA response in CRPC. Larger, prospective studies will be required to confirm our findings.